ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tapinarof

Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.

Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.

Drug pageTapinarof: every studyMany companies study it; this page follows only the 25 they lead. All 34 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 26, 202225 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon121 open or runningphase 4since Dec 26, 2022May 16, 2019Aug 2027phase 3 · NCT07265479
GlaxoSmithKlineits history only80 open or runningphase 3since Jun 27, 2017Oct 31, 2013none ahead
Welichem Biotechits history only30 open or runningphase 2since Feb 3, 2009Feb 3, 2009none ahead
Sun Pharmaceutical Industriesits history only10 open or runningphase 1since Apr 15, 2026Apr 15, 2026none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Dec 16, 2024Dec 16, 2024none ahead

Also a collaborator on its studies: Teva Pharmaceuticals, IQVIA Biotech, PPD DEVELOPMENT, LP, Q2 Solutions and iCardiac Technologies.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named tapinarofINNProposed as its International Nonproprietary Name in WHO's List 116 · before, WBI-1001
  2. May 16, 2019First study: phase 3 study in PsoriasisFirst studyNCT03956355 · 510 enrolled · United States, Canada
  3. Jun 10, 2019Phase 3 study in PsoriasisNCT03983980 · 515 enrolled · United States, Canada
  4. Jul 23, 2019Phase 3 study in PsoriasisNCT04053387 · 763 enrolled · United States, Canada
  5. Jul 24, 2019Phase 2 study in Plaque PsoriasisNCT04042103 · 21 enrolled · United States
  6. Aug 16, 20212 phase 3 studies in Dermatitis, AtopicNCT05014568, NCT05032859
  7. Oct 28, 20212 phase 3 studiesNCT05172726, NCT05142774
  8. Nov 8, 2021Phase 2 study in Dermatitis, AtopicNCT05186805 · 36 enrolled · United States, Canada
  9. Dec 26, 2022Phase 4 study in PsoriasisNCT05680740 · 34 enrolled · United States
  10. Mar 14, 2023Phase 4 study in PsoriasisNCT05789576 · 31 enrolled · United States
  11. Nov 21, 2025Phase 3 study in Dermatitis, AtopicNCT07265479 · 187 enrolled · United States, Canada
  12. Oct 5, 2026Phase 3 study suspendedStudy stoppedNCT07265479

Ahead

  1. Aug 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT07265479

TargetBeta

AHR →read by rule
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule

Studies

All 12 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07265479Dermatitis, Atopic · United States, Canada3Active, not recruitingAug 2027187
NCT05789576Psoriasis · United States4CompletedJun 30, 202331
NCT05680740Psoriasis · United States4CompletedMay 18, 202334
NCT05186805Dermatitis, Atopic · United States, Canada2CompletedAug 24, 202236
NCT05142774Dermatitis, Atopic · United States, Canada3CompletedFeb 29, 2024728
NCT05172726Plaque Psoriasis · United States, Canada3CompletedOct 14, 202658
NCT05032859Dermatitis, Atopic · United States, Canada3CompletedFeb 3, 2023406
NCT05014568Dermatitis, Atopic · United States, Canada3CompletedMar 30, 2023407
NCT04042103Plaque Psoriasis · United States2CompletedJan 9, 202021
NCT04053387Psoriasis · United States, Canada3CompletedApr 6, 2021763
NCT03983980Psoriasis · United States, Canada3CompletedMay 13, 2020515
NCT03956355Psoriasis · United States, Canada3CompletedMay 26, 2020510

How it is read

Names in the registry

  • “Tapinarof cream, 1%”, 4 entries
  • “tapinarof cream, 1%”, 4 entries
  • “WBI-1001”, 3 entries
  • “Tapinarof”, 2 entries
  • “GSK2894512 1% Cream”, 2 entries

Codes read as this program: GSK2894512.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.